Azacitidine 100mg Injection

Azacitidine 100mg Injection is a pioneering pyrimidine nucleoside analog of cytidine that serves as the backbone of epigenetic therapy for blood cancers. Unlike traditional chemotherapy that simply destroys rapidly dividing cells, Azacitidine functions as a hypomethylating agent. It works by inhibiting the enzyme DNA methyltransferase, which is responsible for adding methyl groups to DNA. In many cancers, excessive methylation “silences” crucial tumor suppressor genes—the body’s natural brakes on cell growth. By blocking this enzyme, Azacitidine removes these methyl groups (hypomethylation), effectively waking up these dormant genes and restoring the cell’s ability to regulate its own growth and maturation. Additionally, at higher doses, it exerts a direct cytotoxic effect by incorporating itself into RNA and DNA, dismantling the cellular machinery of abnormal hematopoietic cells. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML), offering a survival advantage by reprogramming the cancer cell’s genetic software.

The 100mg vial serves as the standard dosing unit for preparing the suspension required for administration. Azacitidine is most commonly administered via subcutaneous injection (under the skin) into the upper arm, thigh, or abdomen, although it can be given intravenously. The standard treatment cycle typically involves daily injections for 7 consecutive days, repeated every 28 days. The 100mg strength facilitates the preparation of the standard 75 mg/m² dose, allowing for adjustments based on the patient’s body surface area. This regimen is designed to maintain continuous epigenetic pressure on the bone marrow, gradually improving blood counts over several cycles.

Indications / Uses of Azacitidine 100mg Injection

Azacitidine 100mg Injection is commonly prescribed for the specialized management of the following hematological malignancies:

• Myelodysplastic Syndromes (MDS): It is indicated for the treatment of patients with the following FAB myelodysplastic syndrome subtypes: Refractory Anemia (RA) or Refractory Anemia with Ringed Sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), Refractory Anemia with Excess Blasts (RAEB), Refractory Anemia with Excess Blasts in Transformation (RAEB-T), and Chronic Myelomonocytic Leukemia (CMMoL).
• Acute Myeloid Leukemia (AML): It is indicated for the treatment of adult patients with newly diagnosed AML with 20-30% bone marrow blasts who are not candidates for intensive induction chemotherapy.

Key Features

• Epigenetic Modulation: The primary feature of Azacitidine is its ability to reverse DNA hypermethylation, restoring the function of tumor suppressor genes.
• Survival Benefit: It was the first drug to demonstrate a significant extension of overall survival in higher-risk MDS patients compared to conventional care.
• Dual Mechanism: It combines gene regulation (hypomethylation) with direct cell killing (cytotoxicity) depending on the intracellular concentration.
• Subcutaneous Route: The subcutaneous formulation allows for outpatient administration without the absolute need for IV access, though injection site care is required.
• Broad MDS Efficacy: It is effective across all five major subtypes of MDS according to the FAB classification.

Storage for Azacitidine 100mg Injection

To preserve the chemical stability of the active ingredients, unreconstituted vials of Azacitidine 100mg Injection should be stored at controlled room temperature, typically between 20°C and 25°C (68°F to 77°F). Once reconstituted, the stability is very limited. If preparing for subcutaneous use, the suspension may be stored for up to 1 hour at room temperature or up to 8 hours under refrigeration (2°C to 8°C). It is vital to use the suspension within these strict timeframes to ensure potency. Store the medication in a secure, professional medical environment strictly out of the reach of children.

Important Note on Azacitidine 100mg Injection

The administration of Azacitidine 100mg Injection is associated with specific monitoring requirements. Myelosuppression (anemia, neutropenia, and thrombocytopenia) is a common and expected side effect, particularly during the first two cycles. Complete Blood Counts (CBC) must be monitored frequently, and dose adjustments may be necessary if counts drop dangerously low.

Renal Toxicity: Azacitidine and its metabolites are excreted by the kidneys. Renal function (serum creatinine and BUN) must be monitored before starting therapy and before each subsequent cycle. Patients with renal impairment require careful observation for signs of renal tubular acidosis.

Hepatic Toxicity: In patients with pre-existing severe liver impairment, the drug can potentially induce hepatic coma; it is generally contraindicated in patients with advanced malignant hepatic tumors. Injection Site Reactions (redness, bruising, pain) are very common with subcutaneous administration; rotating injection sites is mandatory. Azacitidine 100mg Injection can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and monitoring protocols, healthcare providers can safely maximize the therapeutic benefits of Azacitidine 100mg Injection.